Adma Biologics, Inc.
ADMA- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001368514
No open-market purchases or sales by Adma Biologics, Inc. insiders were filed in the last 90 days; 322 institutions reported holding it in 13F filings for Q2 2026, worth $1.70B in total; superinvestors Duquesne Family Office and Fundsmith hold it.
13F holders, Q1 2026
Institutional positions in Adma Biologics, Inc. as of Mar 31, 2026. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 358
- +9 vs. Q4 2025
- Shares held
- 211.9M
- +12.5M (+6.3%) vs. Q4 2025
- Total value
- $1.91B
- −$1.72B (−47.4%) vs. Q4 2025
- New holders
- 70
- 136 more added
- Sold out
- 61
- 109 more reduced
8 institutions that held it in Q4 2025 haven't filed for Q1 2026 yet. Not filing isn't selling, so they aren't counted as sold out or in the changes above.
Compare with Q4 2025: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting ADMA on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 322 | $1.70B |
| Q1 2026 | 358 | $1.91B |
| Q4 2025 | 357 | $4.02B |
| Q3 2025 | 366 | $3.28B |
| Q2 2025 | 369 | $3.84B |
| Q1 2025 | 347 | $4.07B |
| Q4 2024 | 321 | $3.50B |
| Q3 2024 | 306 | $4.16B |
| Q2 2024 | 253 | $2.03B |
| Q1 2024 | 214 | $1.16B |
| Q4 2023 | 184 | $764.6M |
| Q3 2023 | 188 | $612.7M |
| Q2 2023 | 179 | $610.6M |
| Q1 2023 | 163 | $547.2M |
| Q4 2022 | 160 | $592.2M |
| Q3 2022 | 130 | $315.4M |
| Q2 2022 | 113 | $236.0M |
| Q1 2022 | 105 | $189.9M |
| Q4 2021 | 88 | $137.1M |
| Q3 2021 | 72 | $47.3M |
| Q2 2021 | 90 | $68.6M |
| Q1 2021 | 104 | $85.4M |
Institutions, Q1 2026
Shares, value and share of portfolio for each institution holding Adma Biologics, Inc.; share changes are against Q4 2025.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| O'Shaughnessy Asset Management, LLC | 0 | $0 | 0.00% | −11,582−100.0% | Sold out |
| Ashton Thomas Private Wealth, LLC | 0 | $0 | 0.00% | −11,463−100.0% | Sold out |
| Foster Group, Inc. | 0 | $0 | 0.00% | −10,781−100.0% | Sold out |
| Snowden Capital Advisors LLC | 0 | $0 | 0.00% | −10,617−100.0% | Sold out |
| Natixis | 0 | $0 | 0.00% | −4,387−100.0% | Sold out |
| Kestra Advisory Services, LLC | 0 | $0 | 0.00% | −3,959−100.0% | Sold out |
| Nkcfo LLC | 0 | $0 | 0.00% | −2,560−100.0% | Sold out |
| Optima Capital LLC | 0 | $0 | 0.00% | −2,000−100.0% | Sold out |
| Quest Partners LLC | 0 | $0 | 0.00% | −1,677−100.0% | Sold out |
| Clear Street Markets LLC | 0 | $0 | 0.00% | −1,609−100.0% | Sold out |
| Financial Management Professionals, Inc. | 0 | $0 | 0.00% | −1,182−100.0% | Sold out |
| Flagship Harbor Advisors, LLC | 0 | $0 | 0.00% | −1,000−100.0% | Sold out |
| Daiwa Securities Group Inc. | 0 | $0 | 0.00% | −670−100.0% | Sold out |
| Danske Bank A/S | 0 | $0 | 0.00% | −500−100.0% | Sold out |
| Greenline Wealth Management LLC | 0 | $0 | 0.00% | −174−100.0% | Sold out |
| Truvestments Capital LLC | 0 | $0 | 0.00% | −158−100.0% | Sold out |
| Toth Financial Advisory Corp | 0 | $0 | 0.00% | −105−100.0% | Sold out |
| UMA Financial Services, Inc. | 0 | $0 | 0.00% | −32−100.0% | Sold out |
| Assetmark, Inc | 0 | $0 | 0.00% | −5−100.0% | Sold out |
| Vanguard Group Inc | – | – | – | – | Not filed |
| Comerica Bank | – | – | – | – | Not filed |
| CIBC World Markets Corp | – | – | – | – | Not filed |
| Janney Capital Management LLC | – | – | – | – | Not filed |
| CIBC Private Wealth Group, LLC | – | – | – | – | Not filed |
| Global Retirement Partners, LLC | – | – | – | – | Not filed |
| ORG Partners LLC | – | – | – | – | Not filed |
| New Millennium Group LLC | – | – | – | – | Not filed |